PHE News

PHE at ISPOR Europe – November 4th through 8th – Glasgow, Scotland

Precision Health Economics will be well represented at ISPOR’s 20th Annual European Congress, to be held November 4-8 at the Scottish Events Campus, Glasgow, Scotland.

READ MORE

PHE's Goldman in Fortune: Innovative Drugs Deserve Innovative Pricing

PHE cofounder Dana Goldman contributes a new commentary for Fortune.com, discussing the significance of the risk sharing agreement established between CMS and Novartis over Kymriah, the first gene therapy to achieve FDA approval.

READ MORE

PHE’s Shafrin Defines Precision Medicine for US News & World Report

In a new commentary for US News & World Report, Precision Health Economics’ senior research economist Jason Shafrin defines and elaborates on the field of precision medicine.

READ MORE

PHE Researchers Publish New Study Comparing Clinical Trial Efficacy and Real-World Effectiveness for Cancer Therapies

A new study by PHE researchers recently published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), examines the relationship between the efficacy of randomized controlled trials (RCTs) and real-world effectiveness for oncology treatments.

READ MORE

Managed Healthcare Connect Presents Details of New PHE RA Study

Christina Vogt with Managed Healthcare Connect recently provided a breakdown and analysis of a new PHE study on the impact of ACPA status on patient costs associated with rheumatoid arthritis.

READ MORE
 
  • Academic Insights at

    the Speed of Business

     
  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

     
  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

     
  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

     
  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Value, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

     
  • Academic Insights at

    the Speed of Business